How can the evaluation of genetic tests be enhanced? Lessons learned from the ACCE framework and evaluating genetic tests in the United Kingdom
about
Genetic testing and common disorders in a public health framework: how to assess relevance and possibilities. Background Document to the ESHG recommendations on genetic testing and common disordersFindings made in gene panel to whole genome sequencing: data, knowledge, ethics - and consequences?Technology assessment and resource allocation for predictive genetic testing: a study of the perspectives of Canadian genetic health care providersFunding decisions for newborn screening: a comparative review of 22 decision processes in EuropePersonal genome testing: test characteristics to clarify the discourse on ethical, legal and societal issuesNon-invasive prenatal testing: ethical issues exploredEvaluating genomic tests from bench to bedside: a practical frameworkPersonalizing medicine with clinical pharmacogeneticsRevealing barriers and facilitators to use a new genetic test: comparison of three user involvement methods.Personalized medicine and access to health care: potential for inequitable access?Was it worth it? Patients' perspectives on the perceived value of genomic-based individualized medicine.Patients' perceived utility of whole-genome sequencing for their healthcare: findings from the MedSeq project.Array-based comparative genomic hybridization for investigating chromosomal abnormalities in patients with learning disability: systematic review meta-analysis of diagnostic and false-positive yields.CYP2C8*3 increases risk of neuropathy in breast cancer patients treated with paclitaxelRapid ACCE: experience with a rapid and structured approach for evaluating gene-based testing.Economic methods for valuing the outcomes of genetic testing: beyond cost-effectiveness analysis.Issues surrounding the health economic evaluation of genomic technologies.Against Genetic Tests for Athletic Talent: The Primacy of the Phenotype.Requirements for comprehensive pharmacogenetic genotyping platforms.In vitro screening of embryos by whole-genome sequencing: now, in the future or never?Review of the Reported Measures of Clinical Validity and Clinical Utility as Arguments for the Implementation of Pharmacogenetic Testing: A Case Study of Statin-Induced Muscle Toxicity.The challenge of implementing genetic tests with clinical utility while avoiding unsound applications.Cost effective assay choice for rare disease study designsClinical utility of genetic and genomic services: context matters.The development and validation of a decision-analytic model representing the full disease course of acute myeloid leukemia.Evaluating the utility of personal genomic information.Psychological and behavioural impact of genetic testing smokers for lung cancer risk: a phase II exploratory trial.Development and description of GETT: a genetic testing evidence tracking tool.What is the clinical utility of genetic testing?"I'm Healthy, It's Not Going To Be Me": Exploring experiences of carriers identified through a population reproductive genetic carrier screening panel in Australia.Concepts for the translation of genome-based innovations into public health: a comprehensive overview.Guidance for considering ethical, legal, and social issues in health technology assessment: Application to genetic screeningImplementing noninvasive prenatal fetal sex determination using cell-free fetal DNA in the United KingdomThe overarching framework of translation and integration into healthcare: a case for the LAL modelACCE, Pharmacogenomics, and Stopping Clinical Trials: Time to Extend the CONSORT Statement?
P2860
Q22330767-0733FD43-8AD3-4876-8399-0FF59CEAFAAAQ31114379-417049B6-59BE-47AA-840A-299288DD0660Q33470740-7F2E735C-52CF-4AD8-AE1D-DD01F525A25BQ33742237-3E020CD0-C737-4D67-91D7-CDDCF0544707Q33932189-E7E3F9BA-B480-47A2-AE80-4944DB54AB55Q34328617-7FF916B9-E1C0-4D7D-952A-106353F87E6CQ34451291-8A63E86C-0046-4E4D-9B42-19589CA0FFDAQ35791989-0B08607F-99B1-491B-BECB-57ECA27378E9Q36288248-BC5EA3D2-9371-45FC-88D6-D896919A2BD5Q36543050-10460B83-71DD-439B-BEF5-463D1012EEFBQ36698414-B39E5AF1-D77F-4FCF-9412-78DEE89DECC2Q36724985-4AAAA8A8-FFF8-4199-8C2E-8A274D387917Q36737126-470F1778-0CE9-45BD-9187-304AEF9783B2Q36862832-A08BA252-0D36-427A-9D72-0F9D2E7ACE44Q36897931-93F2F90A-C78C-45D6-A5E8-EE1C20189E1CQ37315305-511065BE-C0FC-41C5-8900-F478BD890B3EQ37541151-5673EFF7-1974-4E93-BE46-6FAA7E6805F9Q38539897-1E96AACC-67BD-4336-BA7F-D666364AA10AQ38859829-7BB22688-BC8F-409A-A789-F5BA6AC6FAA8Q39257446-BB56E6E0-5693-41EB-B4BB-68136416A862Q41526681-8FBD2070-F12F-4924-B249-FD44D3350F8DQ41868650-ADB4DEF9-DB6A-413A-A994-9C98CD1751E4Q42707077-3CF910AF-1469-4409-8BFB-52854EB348ADQ42734175-F97EEDD1-24A6-41BB-BC65-E1EFC56E4BC6Q45095746-C0E6B20F-6055-4692-BC99-AB2677680DE0Q47593006-A12A650C-F018-4F4F-B60C-A091BF1963FCQ48348413-A987210C-6203-4842-BF11-41E03DAC72C5Q50697702-E0C768FF-E793-4E28-9732-76C85BD2AB15Q52012351-56C53F01-18A2-4968-8F5A-885405583618Q53106013-208FFD93-AE30-462A-AD0B-14AE2725F386Q54257580-196995F2-1E8C-45D4-B4F1-B06263E904E6Q57301910-E02F068A-5DF4-426A-9570-D3397A2A75EDQ57839586-382FDDE3-1C4C-492D-B0E8-05E06E201693Q57899345-4E9D9034-0F59-4B73-8093-DD9390C8D357Q57989224-B9E026E4-69B4-45A7-87E5-9455E07E0AF4
P2860
How can the evaluation of genetic tests be enhanced? Lessons learned from the ACCE framework and evaluating genetic tests in the United Kingdom
description
scientific article published on 01 September 2005
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована у вересні 2005
@uk
name
How can the evaluation of gene ...... ic tests in the United Kingdom
@en
How can the evaluation of gene ...... ic tests in the United Kingdom
@nl
type
label
How can the evaluation of gene ...... ic tests in the United Kingdom
@en
How can the evaluation of gene ...... ic tests in the United Kingdom
@nl
prefLabel
How can the evaluation of gene ...... ic tests in the United Kingdom
@en
How can the evaluation of gene ...... ic tests in the United Kingdom
@nl
P2093
P2860
P1433
P1476
How can the evaluation of gene ...... ic tests in the United Kingdom
@en
P2093
Mark Kroese
Ron Zimmern
Simon Sanderson
P2860
P304
P356
10.1097/01.GIM.0000179941.44494.73
P407
P577
2005-09-01T00:00:00Z
P6179
1028518646